We are live on ! Find out more
BTAI icon

BioXcel Therapeutics
BTAI

96 hedge funds and large institutions have $274M invested in BioXcel Therapeutics in 2022 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 34 increasing their positions, 28 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 12

21% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 28

3% more funds holding

Funds holding: 93 → 96 (+3)

0.18% less ownership

Funds ownership: 3.11% → 2.93% (-0.18%)

3% less capital invested

Capital invested by funds: $283M → $274M (-$9.19M)

21% less call options, than puts

Call options by funds: $3.46M | Put options by funds: $4.4M

Holders
96
Holders Change
+3
Holders Change %
+3.23%
% of All Funds
1.51%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
16
Increased
34
Reduced
28
Closed
12
Calls
$3.46M
Puts
$4.4M
Net Calls
-$939K
Net Calls Change
-$2.86M

Top Buyers

Rank Fund Capital Flow
1
RCMNY
Rubric Capital Management (New York)
New York
+$4.86M
2
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$1.74M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
+$1.47M
4
State Street
State Street
Massachusetts
+$1.01M
5
Jane Street
Jane Street
New York
+$988K

Top Sellers

Rank Fund Capital Flow
1
AllianceBernstein
AllianceBernstein
Tennessee
-$26.6M
2
Citigroup
Citigroup
New York
-$1.13M
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$968K
4
WMSA
Weiss Multi-Strategy Advisers
New York
-$609K
5
Morgan Stanley
Morgan Stanley
New York
-$429K
Name Holding Trade Value Shares
Change 		Change in
Stake
Rockefeller Capital Management
76
Rockefeller Capital Management
New York
$41K – – –
CG
77
Cutler Group
California
$31K -$14.5K -50 -35%
AIP
78
Ameritas Investment Partners
Nebraska
$28K – – –
MLICM
79
Metropolitan Life Insurance Company (MetLife)
New York
$27.3K -$64.6K -223 -73%
Fifth Third Bancorp
80
Fifth Third Bancorp
Ohio
$23K – – –
Royal Bank of Canada
81
Royal Bank of Canada
Ontario, Canada
$22K -$48.4K -167 -71%
Canada Life
82
Canada Life
Manitoba, Canada
$16K – – –
US Bancorp
83
US Bancorp
Minnesota
$15K -$2.03K -7 -13%
National Bank of Canada
84
National Bank of Canada
Quebec, Canada
$15K -$870 -3 -6%
WTA
85
Washington Trust Advisors
Massachusetts
$5K – – –
WAM
86
Worth Asset Management
Texas
$4K +$6.38K +22 New
SWM
87
Spire Wealth Management
Virginia
$3K – – –
FDCDDQ
88
Federation des caisses Desjardins du Quebec
Quebec, Canada
$2.36K – – –
APC
89
Aspire Private Capital
North Carolina
$2K – – –
LWANC
90
Laurel Wealth Advisors (North Carolina)
North Carolina
$2K – – –
PA
91
Parallel Advisors
California
$2K +$1.45K +5 New
LC
92
Lindbrook Capital
California
$2K +$1.74K +6 New
CAPTRUST Financial Advisors
93
CAPTRUST Financial Advisors
North Carolina
$1K +$580 +2 +200%
HFS
94
Hantz Financial Services
Michigan
$1K +$870 +3 New
Macquarie Group
95
Macquarie Group
Australia
$49 – – –
WMSA
96
Weiss Multi-Strategy Advisers
New York
– -$609K -1,873 Closed
CF
97
CNA Financial
Illinois
– -$292K -897 Closed
VF
98
Virtu Financial
New York
– -$250K -768 Closed
WG
99
Winton Group
United Kingdom
– -$249K -766 Closed
ECM
100
ExodusPoint Capital Management
New York
– -$213K -656 Closed
1 2 3
4
5

BTAI Hedge Fund Activity: Q1 2022 in Review

96 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in BioXcel Therapeutics (BTAI) for Q1 2022, worth a combined $274M — down 3.2% from $283M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new BTAI positions and 12 closed out — a net gain of 4 holders — while 34 added to existing stakes and 28 trimmed.

The largest buyer was Rubric Capital Management (New York), opening a new position worth an estimated $4.86M. The largest seller was AllianceBernstein, cutting an estimated $26.6M.

  • 96 institutional investors held BioXcel Therapeutics (BTAI) as of Q1 2022, up from 93 in Q4 2021.
  • Funds reported $274M of BioXcel Therapeutics stock for Q1 2022, down 3.2% quarter-over-quarter.
  • 16 funds opened new BioXcel Therapeutics positions in Q1 2022 and 12 closed out, a net change of +4 holders.
  • The largest BioXcel Therapeutics buyer in Q1 2022 was Rubric Capital Management (New York), an estimated $4.86M added.
  • The largest BioXcel Therapeutics seller in Q1 2022 was AllianceBernstein, an estimated $26.6M sold.

Based on aggregated 13F filings for Q1 2022.